{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:07:21Z","timestamp":1772773641837,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The purpose of this study was to compare the impact of intravitreal dexamethasone (DEX) implant during a 12-month period in nondiabetic and diabetic patients without diabetic retinopathy (DR) as a treatment for refractory pseudophakic cystoid macular edema (PCME) following prior treatment with topical nepafenac 0.1% and prednisolone 1%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Forty-two consecutive medical records of patients diagnosed with PCME after uneventful cataract surgery were included. The outcomes measured included best corrected visual acuity (BCVA) and central foveal thickness (CFT). Linear regression analysis was statistically applied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Following topical treatment, nondiabetic and diabetic subjects presented a mean\u2009\u00b1\u2009SD gain of \u2212\u20090.11\u2009\u00b1\u20090.11 and \u2212\u20090.18\u2009\u00b1\u20090.11 BCVA logMAR and a CFT reduction of \u2212\u200943.42\u2009\u00b1\u200953.66\u00a0\u00b5m and \u2212\u200958.76\u2009\u00b1\u200936.28\u00a0\u00b5m, respectively. The mean BCVA gain at month 12 subsequent to DEX implantation was \u2212\u20090.35\u2009\u00b1\u20090.17 in nondiabetic (p\u2009&lt;\u20090.001) and \u2212\u20090.55\u2009\u00b1\u20090.26 in diabetic patients (p\u2009&lt;\u20090.001), with CFT reductions of \u2212\u2009195.71\u2009\u00b1\u200993.23\u00a0\u00b5m (p\u2009&lt;\u20090.001) and \u2212\u2009260.81\u2009\u00b1\u2009198.69\u00a0\u00b5m (p\u2009&lt;\u20090.001), respectively. Patients who responded with better VA after topical treatment presented better visual outcomes at month 12 following DEX implantation (r<jats:sup>2<\/jats:sup>\u2009=\u20090.46; <jats:italic>rho<\/jats:italic>\u2009=\u2009\u2212\u20090.71, p\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Nondiabetic and diabetic patients without DR demonstrated similar results after DEX implant after combined topical therapy, suggesting that selected diabetic patients may have a response comparable to that of nondiabetic patients with PCME.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40942-023-00489-2","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T07:02:30Z","timestamp":1695020550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pseudophakic macular edema in nondiabetic and diabetic patients without diabetic retinopathy treated with intravitreal dexamethasone implant"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8921-9444","authenticated-orcid":false,"given":"Magna Vanessa","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Mauricio Botto","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia Delalibera","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabricio Tadeu","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Leonardo Cruvinel","family":"Isaac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Avila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"489_CR1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/s0886-3350(03)00582-0","volume":"30","author":"CL Lobo","year":"2004","unstructured":"Lobo CL, Faria PM, Soares MA, et al. Macular alterations after small-incision cataract surgery. J Cataract Refract Surg. 2004;30:752\u201360. https:\/\/doi.org\/10.1016\/s0886-3350(03)00582-0.","journal-title":"J Cataract Refract Surg"},{"key":"489_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1442-9071.2011.02638.x","volume":"40","author":"M Vukicevic","year":"2012","unstructured":"Vukicevic M, Gin T, Al-Qureshi S. Prevalence of optical coherence tomography-diagnosed postoperative cystoid macular oedema in patients following uncomplicated phaco-emulsification cataract surgery. Clin Exp Ophthalmol. 2012;40:282\u20137. https:\/\/doi.org\/10.1111\/j.1442-9071.2011.02638.x.","journal-title":"Clin Exp Ophthalmol"},{"key":"489_CR3","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1097\/iae.0000000000001747","volume":"38","author":"E Fleissig","year":"2018","unstructured":"Fleissig E, Cohen S, Iglicki M, et al. Changes in choroidal thickness in clinically significant pseudophakic cystoid macular edema. Retina (Philadelphia, Pa). 2018;38:1629\u201335. https:\/\/doi.org\/10.1097\/iae.0000000000001747.","journal-title":"Retina (Philadelphia, Pa)"},{"key":"489_CR4","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/aos.14007","volume":"97","author":"C Taipale","year":"2018","unstructured":"Taipale C, Holmstrom EJ, Ilveskoski L, et al. Incidence of pseudophakic cystoid macular edema in eyes with and without pupil expansion device. Acta Ophthalmol. 2018;97:688\u201394. https:\/\/doi.org\/10.1111\/aos.14007.","journal-title":"Acta Ophthalmol"},{"key":"489_CR5","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00417-018-3954-4","volume":"256","author":"F Schaub","year":"2018","unstructured":"Schaub F, Adler W, Enders P, et al. Preexisting epiretinal membrane is associated with pseudophakic cystoid macular edema. Graefe\u2019s Arch Clin Exp Ophthalmol Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2018;256:909\u201317. https:\/\/doi.org\/10.1007\/s00417-018-3954-4.","journal-title":"Graefe's Arch Clin Exp Ophthalmol Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"},{"key":"489_CR6","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1097\/iae.0000000000002298","volume":"39","author":"S Copete","year":"2018","unstructured":"Copete S, Marti-Rodrigo P, Muniz-Vidal R, et al. Preoperative vitreoretinal interface abnormalities on spectral domain optical coherence tomography as risk factor for pseudophakic cystoid macular edema after phacoemulsification. Retina (Philadelphia, Pa). 2018;39:2225\u201332. https:\/\/doi.org\/10.1097\/iae.0000000000002298.","journal-title":"Retina (Philadelphia, Pa)"},{"key":"489_CR7","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jcrs.2007.05.013","volume":"33","author":"BA Henderson","year":"2007","unstructured":"Henderson BA, Kim JY, Ament CS, et al. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007;33:1550\u20138. https:\/\/doi.org\/10.1016\/j.jcrs.2007.05.013.","journal-title":"J Cataract Refract Surg"},{"key":"489_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ophtha.2015.10.001","volume":"123","author":"CJ Chu","year":"2016","unstructured":"Chu CJ, Johnston RL, Buscombe C, et al. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology. 2016;123:316\u201323. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.001.","journal-title":"Ophthalmology"},{"key":"489_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/bjophthalmol-2016-308617","volume":"101","author":"A Pollack","year":"2017","unstructured":"Pollack A, Staurenghi G, Sager D, et al. Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy. Br J Ophthalmol. 2017;101:423\u20137. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-308617.","journal-title":"Br J Ophthalmol"},{"key":"489_CR10","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/S0886-3350(02)01319-6","volume":"28","author":"M Somaiya","year":"2002","unstructured":"Somaiya M, Burns JD, Mintz R, et al. Factors affecting visual outcomes after small-incision phacoemulsification in diabetic patients. J Cataract Refract Surg. 2002;28:1364\u201371.","journal-title":"J Cataract Refract Surg"},{"key":"489_CR11","doi-asserted-by":"publisher","unstructured":"Arevalo JF, Maia M, Garcia-Amaris RA, et al. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American collaborative retina study group results. Ophthalmology. 2009; 116: 1481\u20131487, 1487.e1481. https:\/\/doi.org\/10.1016\/j.ophtha.2009.04.006.","DOI":"10.1016\/j.ophtha.2009.04.006"},{"key":"489_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.5935\/0004-2749.20160033","volume":"79","author":"JM Garcia","year":"2016","unstructured":"Garcia JM, Isaac DL, Avila MP. Dexamethasone 0.7 mg implants in the management of pseudophakic cystoid macular edema. Arq Bras Oftalmol. 2016;79:113\u20135. https:\/\/doi.org\/10.5935\/0004-2749.20160033.","journal-title":"Arq Bras Oftalmol"},{"key":"489_CR13","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1089\/jop.2012.0032","volume":"28","author":"S Demirel","year":"2012","unstructured":"Demirel S, Batioglu F, Ozmert E. Intravitreal ranibizumab for the treatment of cystoid macular edema in Irvine-Gass syndrome. J Ocular Pharmacol Ther. 2012;28:636\u20139. https:\/\/doi.org\/10.1089\/jop.2012.0032.","journal-title":"J Ocular Pharmacol Ther"},{"key":"489_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/opth.s4684","volume":"3","author":"SM Hariprasad","year":"2009","unstructured":"Hariprasad SM, Akduman L, Clever JA, et al. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol (Auckland, NZ). 2009;3:147\u201354. https:\/\/doi.org\/10.2147\/opth.s4684.","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"489_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.18240\/ijo.2018.01.14","volume":"11","author":"A Pareja-Rios","year":"2018","unstructured":"Pareja-Rios A, Ruiz-de la Fuente-Rodriguez P, Bonaque-Gonzalez S, et al. Intravitreal dexamethasone implants for diabetic macular edema. Int J Ophthalmol. 2018;11:77\u201382. https:\/\/doi.org\/10.18240\/ijo.2018.01.14.","journal-title":"Int J Ophthalmol"},{"key":"489_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/02713683.2017.1396615","volume":"43","author":"C Campa","year":"2018","unstructured":"Campa C, Salsini G, Perri P. Comparison of the efficacy of dexamethasone, nepafenac, and bromfenac for preventing pseudophakic cystoid macular edema: an open-label, prospective, randomized controlled trial. Curr Eye Res. 2018;43:362\u20137. https:\/\/doi.org\/10.1080\/02713683.2017.1396615.","journal-title":"Curr Eye Res"},{"key":"489_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.sjopt.2014.10.005","volume":"29","author":"WM Al Zamil","year":"2015","unstructured":"Al Zamil WM. Short-term safety and efficacy of intravitreal 0.7-mg dexamethasone implants for pseudophakic cystoid macular edema. Saudi J Ophthalmol. 2015;29:130\u20134. https:\/\/doi.org\/10.1016\/j.sjopt.2014.10.005.","journal-title":"Saudi J Ophthalmol"},{"key":"489_CR18","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1167\/iovs.12-11463","volume":"54","author":"M Dutra Medeiros","year":"2013","unstructured":"Dutra Medeiros M, Navarro R, Garcia-Arumi J, et al. Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from Irvine-Gass syndrome. Invest Ophthalmol Vis Sci. 2013;54:3320\u20134. https:\/\/doi.org\/10.1167\/iovs.12-11463.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"489_CR19","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.jcrs.2015.10.025","volume":"41","author":"WJ Mayer","year":"2015","unstructured":"Mayer WJ, Kurz S, Wolf A, et al. Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndrome. J Cataract Refract Surg. 2015;41:1954\u201361. https:\/\/doi.org\/10.1016\/j.jcrs.2015.10.025.","journal-title":"J Cataract Refract Surg"},{"key":"489_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2147\/opth.S46399","volume":"7","author":"T Brynskov","year":"2013","unstructured":"Brynskov T, Laugesen CS, Halborg J, et al. Longstanding refractory pseudophakic cystoid macular edema resolved using intravitreal 0.7 mg dexamethasone implants. Clin Ophthalmol (Auckland, NZ). 2013;7:1171\u20134. https:\/\/doi.org\/10.2147\/opth.S46399.","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"489_CR21","doi-asserted-by":"publisher","unstructured":"OZURDEX(R) (Dexamethasone Intravitreal Implant) 0.7 mg as initial therapy in pseudophakic patients with diabetic macular edema, macular edema following retinal vein occlusion, and noninfectious posterior segment uveitis: a case-based discussion. Retina (Philadelphia, Pa). 2019; 39(Suppl 1): S1\u201328. https:\/\/doi.org\/10.1097\/01.iae.0000574292.81105.b2.","DOI":"10.1097\/01.iae.0000574292.81105.b2"},{"key":"489_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3341\/kjo.2018.0106","volume":"33","author":"AGK Altintas","year":"2019","unstructured":"Altintas AGK, Ilhan C. Intravitreal dexamethasone implantation in intravitreal bevacizumab treatment-resistant pseudophakic cystoid macular edema. Korean J Ophthalmol KJO. 2019;33:259\u201366. https:\/\/doi.org\/10.3341\/kjo.2018.0106.","journal-title":"Korean J Ophthalmol KJO"},{"key":"489_CR23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/bjophthalmol-2014-306159","volume":"99","author":"D Bellocq","year":"2015","unstructured":"Bellocq D, Korobelnik JF, Burillon C, et al. Effectiveness and safety of dexamethasone implants for post-surgical macular oedema including Irvine-Gass syndrome: the EPISODIC study. Br J Ophthalmol. 2015;99:979\u201383. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-306159.","journal-title":"Br J Ophthalmol"},{"key":"489_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/bjophthalmol-2016-308544","volume":"101","author":"D Bellocq","year":"2017","unstructured":"Bellocq D, Pierre-Kahn V, Matonti F, et al. Effectiveness and safety of dexamethasone implants for postsurgical macular oedema including Irvine-Gass syndrome: the EPISODIC-2 study. Br J Ophthalmol. 2017;101:333\u201341. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-308544.","journal-title":"Br J Ophthalmol"},{"key":"489_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000365945","volume":"5","author":"V Fenicia","year":"2014","unstructured":"Fenicia V, Balestrieri M, Perdicchi A, et al. Intravitreal injection of dexamethasone implant and ranibizumab in cystoid macular edema in the course of Irvine-Gass syndrome. Case Rep Ophthalmol. 2014;5:243\u20138. https:\/\/doi.org\/10.1159\/000365945.","journal-title":"Case Rep Ophthalmol"},{"key":"489_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000448057","volume":"236","author":"A Klamann","year":"2016","unstructured":"Klamann A, Bottcher K, Ackermann P, et al. Intravitreal dexamethasone implant for the treatment of postoperative macular edema. Ophthalmol J Int d\u2019ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkunde. 2016;236:181\u20135. https:\/\/doi.org\/10.1159\/000448057.","journal-title":"Ophthalmol J Int d'ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkunde"},{"key":"489_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jfo.2015.03.011","volume":"39","author":"C Landre","year":"2016","unstructured":"Landre C, Zourdani A, Gastaud P, et al. Treatment of postoperative cystoid macular edema (Irvine-Gass syndrome) with dexamethasone 0.7 mg intravitreal implant. J francais d\u2019ophtalmologie. 2016;39:5\u201311. https:\/\/doi.org\/10.1016\/j.jfo.2015.03.011.","journal-title":"J francais d'ophtalmologie"},{"key":"489_CR28","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/eye.2016.205","volume":"30","author":"A Sudhalkar","year":"2016","unstructured":"Sudhalkar A, Chhablani J, Vasavada A, et al. Intravitreal dexamethasone implant for recurrent cystoid macular edema due to Irvine-Gass syndrome: a prospective case series. Eye (Lond). 2016;30:1549\u201357. https:\/\/doi.org\/10.1038\/eye.2016.205.","journal-title":"Eye (Lond)"},{"key":"489_CR29","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jcrs.2016.02.031","volume":"42","author":"B Takkar","year":"2016","unstructured":"Takkar B. Dexamethasone implant as an effective treatment option for macular edema in Irvine-Gass syndrome. J Cataract Refract Surg. 2016;42:648. https:\/\/doi.org\/10.1016\/j.jcrs.2016.02.031.","journal-title":"J Cataract Refract Surg"},{"key":"489_CR30","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2147\/opth.S63829","volume":"8","author":"M Sacchi","year":"2014","unstructured":"Sacchi M, Villani E, Gilardoni F, et al. Efficacy of intravitreal dexamethasone implant for prostaglandin-induced refractory pseudophakic cystoid macular edema: case report and review of the literature. Clin Ophthalmol (Auckland, NZ). 2014;8:1253\u20137. https:\/\/doi.org\/10.2147\/opth.S63829.","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"489_CR31","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jcrs.2019.04.025","volume":"45","author":"SB Laursen","year":"2019","unstructured":"Laursen SB, Erichsen JH, Holm LM, et al. Prevention of macular edema in patients with diabetes after cataract surgery. J Cataract Refract Surg. 2019;45:854\u201369. https:\/\/doi.org\/10.1016\/j.jcrs.2019.04.025.","journal-title":"J Cataract Refract Surg"},{"issue":"Suppl 1","key":"489_CR32","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0886-3350(96)80160-X","volume":"22","author":"MV Pande","year":"1996","unstructured":"Pande MV, Spalton DJ, Kerr-Muir MG, et al. Postoperative inflammatory response to phacoemulsification and extracapsular cataract surgery: aqueous flare and cells. J Cataract Refract Surg. 1996;22(Suppl 1):770\u20134.","journal-title":"J Cataract Refract Surg"},{"key":"489_CR33","doi-asserted-by":"publisher","first-page":"4625730","DOI":"10.1155\/2017\/4625730","volume":"2017","author":"V Kakkassery","year":"2017","unstructured":"Kakkassery V, Schultz T, Wunderlich MI, et al. Evaluation of predictive factors for successful intravitreal dexamethasone in pseudophakic cystoid macular edema. J Ophthalmol. 2017;2017:4625730. https:\/\/doi.org\/10.1155\/2017\/4625730.","journal-title":"J Ophthalmol"},{"key":"489_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ajo.2018.09.030","volume":"198","author":"R Danni","year":"2019","unstructured":"Danni R, Taipale C, Ilveskoski L, et al. Diabetes alone does not impair recovery from uneventful cataract surgery. Am J Ophthalmol. 2019;198:37\u201344. https:\/\/doi.org\/10.1016\/j.ajo.2018.09.030.","journal-title":"Am J Ophthalmol"},{"key":"489_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/1120672118799626","volume":"29","author":"SA El Gharbawy","year":"2019","unstructured":"El Gharbawy SA, Darwish EA, Abu Eleinen KG, et al. Efficacy of addition of nepafenac 0.1% to steroid eye drops in prevention of post-phaco macular edema in high-risk eyes. Eur J Ophthalmol. 2019;29:453\u20137. https:\/\/doi.org\/10.1177\/1120672118799626.","journal-title":"Eur J Ophthalmol"},{"key":"489_CR36","doi-asserted-by":"publisher","first-page":"4896","DOI":"10.2174\/1381612825666190206104524","volume":"24","author":"A Grzybowski","year":"2018","unstructured":"Grzybowski A, Kanclerz P. The role of steroids and NSAIDs in prevention and treatment of postsurgical cystoid macular edema. Curr Pharm Des. 2018;24:4896\u2013902. https:\/\/doi.org\/10.2174\/1381612825666190206104524.","journal-title":"Curr Pharm Des"},{"key":"489_CR37","doi-asserted-by":"publisher","first-page":"CD010516","DOI":"10.1002\/14651858.CD010516.pub2","volume":"7","author":"VV Juthani","year":"2017","unstructured":"Juthani VV, Clearfield E, Chuck RS. Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery. Cochrane Database Syst Rev. 2017;7:CD010516. https:\/\/doi.org\/10.1002\/14651858.CD010516.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"489_CR38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3109\/09273948.2016.1147587","volume":"25","author":"B Yuksel","year":"2017","unstructured":"Yuksel B, Uzunel UD, Kerci SG, et al. Comparison of subtenon triamcinolone acetonide injection with topical nepafenac for the treatment of pseudophakic cystoid macular edema. Ocular Immunol Inflamm. 2017;25:513\u20139. https:\/\/doi.org\/10.3109\/09273948.2016.1147587.","journal-title":"Ocular Immunol Inflamm"},{"key":"489_CR39","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000431197","volume":"55","author":"EB Rodrigues","year":"2016","unstructured":"Rodrigues EB, Farah ME, Bottos JM, et al. Nonsteroidal anti-inflammatory drugs in the treatment of retinal diseases. Dev Ophthalmol. 2016;55:212\u201320. https:\/\/doi.org\/10.1159\/000431197.","journal-title":"Dev Ophthalmol"},{"key":"489_CR40","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/aos.14018","volume":"97","author":"R Danni","year":"2019","unstructured":"Danni R, Viljanen A, Aaronson A, et al. Preoperative anti-inflammatory treatment of diabetic patients does not improve recovery from cataract surgery when postoperatively treated with a combination of prednisolone acetate and nepafenac. Acta ophthalmol. 2019;97:589\u201395. https:\/\/doi.org\/10.1111\/aos.14018.","journal-title":"Acta ophthalmol"},{"key":"489_CR41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jcrs.2018.01.029","volume":"44","author":"LHP Wielders","year":"2018","unstructured":"Wielders LHP, Schouten J, Winkens B, et al. European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1. J Cataract Refract Surg. 2018;44:429\u201339. https:\/\/doi.org\/10.1016\/j.jcrs.2018.01.029.","journal-title":"J Cataract Refract Surg"},{"key":"489_CR42","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1080\/09273948.2019.1603313","volume":"27","author":"M Dysli","year":"2019","unstructured":"Dysli M, Ruckert R, Munk MR. Differentiation of underlying pathologies of macular edema using spectral domain optical coherence tomography (SD-OCT). Ocular Immunol Inflamm. 2019;27:474\u201383. https:\/\/doi.org\/10.1080\/09273948.2019.1603313.","journal-title":"Ocular Immunol Inflamm"},{"key":"489_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/iae.0000000000002342","author":"I Hecht","year":"2018","unstructured":"Hecht I, Bar A, Rokach L, et al. Optical coherence tomography biomarkers to distinguish diabetic macular edema from pseudophakic cystoid macular edema using machine learning algorithms. Retina (Philadelphia, Pa). 2018. https:\/\/doi.org\/10.1097\/iae.0000000000002342.","journal-title":"Retina (Philadelphia, Pa)"},{"key":"489_CR44","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1136\/bjophthalmol-2017-311240","volume":"102","author":"R Sacconi","year":"2018","unstructured":"Sacconi R, Corbelli E, Carnevali A, et al. Optical coherence tomography angiography in pseudophakic cystoid macular oedema compared to diabetic macular oedema: qualitative and quantitative evaluation of retinal vasculature. Br J ophthalmol. 2018;102:1684\u201390. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311240.","journal-title":"Br J ophthalmol"},{"key":"489_CR45","doi-asserted-by":"publisher","first-page":"582060","DOI":"10.1155\/2015\/582060","volume":"2015","author":"F Semeraro","year":"2015","unstructured":"Semeraro F, Cancarini A, dell\u2019Omo R, et al. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res. 2015;2015:582060. https:\/\/doi.org\/10.1155\/2015\/582060.","journal-title":"J Diabetes Res"},{"key":"489_CR46","doi-asserted-by":"publisher","first-page":"E716","DOI":"10.3390\/jcm8050716","volume":"8","author":"A Grzybowski","year":"2019","unstructured":"Grzybowski A, Kanclerz P, Huerva V, et al. Diabetes and phacoemulsification cataract surgery: difficulties, risks and potential complications. J Clin Med. 2019;8:E716. https:\/\/doi.org\/10.3390\/jcm8050716.","journal-title":"J Clin Med"},{"issue":"5","key":"489_CR47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1159\/000522504","volume":"245","author":"L Badrinarayanan","year":"2022","unstructured":"Badrinarayanan L, Rishi P, George R, Sankara Nethralaya Vitreo-Retinal group (SNVR), et al. Incidence, risk factors, treatment, and outcome of ocular hypertension following intravitreal steroid injections: a comparative study. Ophthalmologica. 2022;245(5):431\u20138. https:\/\/doi.org\/10.1159\/000522504.","journal-title":"Ophthalmologica"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-023-00489-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-023-00489-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-023-00489-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T03:02:31Z","timestamp":1700449351000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-023-00489-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["489"],"URL":"https:\/\/doi.org\/10.1186\/s40942-023-00489-2","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"assertion":[{"value":"15 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Ethics and Research Committee System through Plataforma Brasil (Protocol Number 28975120.3.0000.5078). Patient consent was not required due to the retrospective nature of the study and the use of only anonymized data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}